Literature DB >> 16436712

Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.

Emmanuelle Varon1, Serge Houssaye, Sophie Grondin, Laurent Gutmann.   

Abstract

With respect to pneumococci, there is a need to detect first-step mutants with reduced fluoroquinolone (FQ) susceptibility from which second-step, resistant mutants are likely to be selected in the presence of antipneumococcal FQs. Here, we describe an interpretative disk diffusion test, of which three options are presented, that allows the distinction between first- and second-step mutants. Using five FQ disks (pefloxacin, norfloxacin, levofloxacin, ciprofloxacin, and sparfloxacin, option 1), all known mechanisms of altered FQ susceptibility found in first-step mutants (ParC, ParE, GyrA, or efflux) and in second-step mutants (ParC and GyrA or ParE and GyrA) can be accurately detected, making this option a useful epidemiological tool. Using three FQ disks (pefloxacin, norfloxacin, and levofloxacin, option 2), the most prevalent FQ-resistant mutants, but not the first-step GyrA mutants, can be detected. With only two FQ disks (norfloxacin and levofloxacin) in the third and simplest option, first-step mutants can be distinguished from second-step mutants, however, without differentiation of ParC, ParE, or efflux alterations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436712      PMCID: PMC1366886          DOI: 10.1128/AAC.50.2.572-579.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.

Authors:  M E Jones; D F Sahm; N Martin; S Scheuring; P Heisig; C Thornsberry; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain.

Authors:  C García-Rey; L Aquilar; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

3.  New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.

Authors:  C Janoir; E Varon; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

4.  Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.

Authors:  D C Richardson; D Bast; A McGeer; D E Low
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

6.  A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae.

Authors:  K Weiss; C Restieri; R Gauthier; M Laverdière; A McGeer; R J Davidson; L Kilburn; D J Bast; J de Azavedo; D E Low
Journal:  Clin Infect Dis       Date:  2001-07-20       Impact factor: 9.079

7.  Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.

Authors:  S Hartman-Neumann; K DenBleyker; L A Pelosi; L E Lawrence; J F Barrett; T J Dougherty
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

8.  Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.

Authors:  E Pestova; R Beyer; N P Cianciotto; G A Noskin; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

9.  Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.

Authors:  L M Weigel; G J Anderson; R R Facklam; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

10.  Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.

Authors:  V J Heaton; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

View more
  5 in total

1.  First molecular characterization of fluoroquinolone resistance in Aerococcus spp.

Authors:  Vincent Cattoir; Alfred Kobal; Patrick Legrand
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation.

Authors:  M de Cueto; J M Rodríguez; M J Soriano; L López-Cerero; J Venero; A Pascual
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

3.  Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.

Authors:  S Page; F Vernel-Pauillac; O O'Connor; S Bremont; F Charavay; P Courvalin; C Goarant; S Le Hello
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

Review 4.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

5.  Host-pathogen interactions and prognosis of critically ill immunocompetent patients with pneumococcal pneumonia: the nationwide prospective observational STREPTOGENE study.

Authors:  Jean-Pierre Bedos; Emmanuelle Varon; Raphael Porcher; Pierre Asfar; Yves Le Tulzo; Bruno Megarbane; Armelle Mathonnet; Anthony Dugard; Anne Veinstein; Kader Ouchenir; Shidasp Siami; Jean Reignier; Arnaud Galbois; Joël Cousson; Sébastien Preau; Olivier Baldesi; Jean-Philippe Rigaud; Bertrand Souweine; Benoit Misset; Frederic Jacobs; Florent Dewavrin; Jean-Paul Mira
Journal:  Intensive Care Med       Date:  2018-11-19       Impact factor: 17.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.